<DOC>
	<DOCNO>NCT02322619</DOCNO>
	<brief_summary>An open label , balance , randomize , two-treatment , two-period , two-sequence , single dose , crossover , oral bioequivalence study human subject fasting condition .</brief_summary>
	<brief_title>Bio-equivalency Study Moxifloxacin Tablets , 400 mg Under Fasting Conditions</brief_title>
	<detailed_description>An open label , balance , randomize , two-treatment , two-period , two-sequence , single dose , crossover , oral bioequivalence study moxifloxacin tablet 400 mg Dr. Reddy 's Laboratories Limited , compare Avelox Â® Tablets 400 mg Bayer Healthcare Pharmaceuticals Inc. healthy , adult , human subject fast condition .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy adult human volunteer 18 45 year age ( inclusive ) live around Ahmedabad city western part India . Having Body Mass Index ( BMI ) 18.5 24.9 ( inclusive ) , calculate weight kg / height m2 . Not significant disease clinically significant abnormal finding screen , medical history , clinical examination , laboratory evaluation , 12 lead ECG Xray chest ( posteroanterior view ) recording . Able understand comply study procedure , opinion investigator . Able give voluntary write informed consent participation trial . In case female subject : Surgically sterilize least 6 month prior study participation If child bear potential willing use suitable effective double barrier contraceptive method intra uterine device study . Pregnancy test must negative . Known hypersensitivity idiosyncratic reaction Moxifloxacin , Quinolones excipients related drug . History presence disease disorder know influence bone metabolism , compromise haemopoietic , renal , hepatic , endocrine , pulmonary , central nervous , cardiovascular , immunological , dermatological , gastrointestinal body system . Ingestion medicine [ include vitamin , herbal supplement enzyme modify drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes strong inducer CYP enzymes ] time within 14 day prior check periodI . In case subject selection discretion Principal Investigator . If QTc interval 450 m ECG measurement time screen . Any history presence hypokalamia , QT prolongation include torsades de pointe . Any history presence asthma ( include aspirin induce asthma ) nasal polyp NSAIDs induce urticaria . A recent history harmful use alcohol ( less 2 year ) , i.e . alcohol consumption 14 standard drink per week men 7 standard drink per week woman ( A standard drink define 360 ml beer 150 ml wine 45 ml 40 % distilled spirit , rum , whisky , brandy etc ) consumption alcohol alcoholic product within 48 hour prior check . Smokers , smoke 10 10 cigarette / day inability abstain smoking study . The presence clinically significant abnormal laboratory value screen . Use recreational drug history drug addiction test positive pre study drug scan . History presence psychiatric disorder . A history difficulty donate blood . Donation blood ( 1 unit 350 mL ) receipt investigational medicinal product participation drug research study within 90 day prior receive first dose study medicine . Note : In case blood loss le equal 200 mL ; subject may enrol 60 day blood donation last sample previous study A positive hepatitis screen include hepatitis B surface antigen and/or HCV antibody . A positive test result HIV antibody . Consumption grape fruit grape fruit product within 48 hour prior check . An unusual diet , whatever reason ( e.g . lowsodium ) , four week prior check Period I . In case subject selection discretion Principal Investigator . Nursing mother ( female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>